Overview

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties, reduce heart failure readmissions to hospitals, and helps patients live longer.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Scios, Inc.
Treatments:
Natriuretic Peptide, Brain
Criteria
Inclusion Criteria:

Hospitalized for the management of acute decompensated heart failure (ADHF) or diagnosed
with ADHF within 48 hours after being hospitalized for another reason; Diagnosis of ADHF is
defined as dyspnea (difficulty breathing) at rest or dyspnea with minimal activity.

Exclusion Criteria:

At high risk for hypotension (low blood pressure); Acute coronary syndrome as primary
diagnosis; History of cardiac valvular stenosis, restrictive cardiomyopathy, hypertrophic
cardiomyopathy, or pericardial tamponade; Previous enrollment in a nesiritide study;
Persistent, uncontrolled hypertension (SBP [systolic blood pressure] >180 mmHg).